Related Experiment Video
Updated: Aug 21, 2026
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Radiotherapy for localized hormone-refractory prostate cancer in Japan
Katsumasa Nakamura1, Teruki Teshima, Yutaka Takahashi
1Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. nakam@radiol.med.kyushu-u.ac.jp
Background:
The role of radiotherapy for patients with localized hormone-refractory cancer has not been well documented.
Materials And Methods:
The Patterns of Care Study in Japan examined the records of 311 patients with prostate cancer treated with radiotherapy during the period 1996--1998. Of them, 61 patients (19.6%) with regionally localized hormone-refractory cancer were selected. Local progression or biochemical failure was observed after a median duration of 15.9 months of androgen deprivation. At the time of radiotherapy, 49 patients (80.4%) had T3-4 tumors and 15 (26.8%) had regional lymph node metastases. External beam radiotherapy was performed with a median total dose of 60 Gy.
Results:
Although distant metastases or regional lymph node metastases were seen in 22 patients (36.1), local progression was observed in one patient (1.6%). The five-year overall and progression-free survival rates were 51.6% and 43.5%, respectively.
Conclusion:
Radiotherapy had an excellent local control rate for hormone-refractory cancer.
